TY  - JOUR
A1  - Otten, Cecile
A1  - Knox, Jessica
A1  - Boulday, Gwenola
A1  - Eymery, Mathias
A1  - Haniszewski, Marta
A1  - Neuenschwander, Martin
A1  - Radetzki, Silke
A1  - Vogt, Ingo
A1  - Haehn, Kristina
A1  - De Luca, Coralie
A1  - Cardoso, Cecile
A1  - Hamad, Sabri
A1  - Igual Gil, Carla
A1  - Roy, Peter
A1  - Albiges-Rizo, Corinne
A1  - Faurobert, Eva
A1  - von Kries, Jens P.
A1  - Campillos, Monica
A1  - Tournier-Lasserve, Elisabeth
A1  - Derry, William Brent
A1  - Abdelilah-Seyfried, Salim
T1  - Systematic pharmacological screens uncover novel pathways involved in cerebral cavernous malformations
JF  - EMBO molecular medicine
N2  - Cerebral cavernous malformations (CCMs) are vascular lesions in the central nervous system causing strokes and seizures which currently can only be treated through neurosurgery. The disease arises through changes in the regulatory networks of endothelial cells that must be comprehensively understood to develop alternative, non-invasive pharmacological therapies. Here, we present the results of several unbiased small-molecule suppression screens in which we applied a total of 5,268 unique substances to CCM mutant worm, zebrafish, mouse, or human endothelial cells. We used a systems biology-based target prediction tool to integrate the results with the whole-transcriptome profile of zebrafish CCM2 mutants, revealing signaling pathways relevant to the disease and potential targets for small-molecule-based therapies. We found indirubin-3-monoxime to alleviate the lesion burden in murine preclinical models of CCM2 and CCM3 and suppress the loss-of-CCM phenotypes in human endothelial cells. Our multi-organism-based approach reveals new components of the CCM regulatory network and foreshadows novel small-molecule-based therapeutic applications for suppressing this devastating disease in patients.
KW  - angiogenesis
KW  - CCM
KW  - ERK5
KW  - indirubin-3-monoxime
KW  - KLF2
Y1  - 2018
U6  - https://doi.org/10.15252/emmm.201809155
SN  - 1757-4676
SN  - 1757-4684
VL  - 10
IS  - 10
PB  - Wiley
CY  - Hoboken
ER  - 
TY  - JOUR
A1  - Igual Gil, Carla
A1  - Jarius, Mirko
A1  - von Kries, Jens P.
A1  - Rohlfing, Anne-Kartin
T1  - Neuronal Chemosensation and Osmotic Stress Response Converge in the Regulation of aqp-8 in C. elegans
JF  - Frontiers in physiology
N2  - Aquaporins occupy an essential role in sustaining the salt/water balance in various cells types and tissues. Here, we present new insights into aqp-8 expression and regulation in Caenorhabditis elegans. We show, that upon exposure to osmotic stress, aqp-8 exhibits a distinct expression pattern within the excretory cell compared to other C. elegans aquaporins expressed. This expression is correlated to the osmolarity of the surrounding medium and can be activated physiologically by osmotic stress or genetically in mutants with constitutively active osmotic stress response. In addition, we found aqp-8 expression to be constitutively active in the TRPV channel mutant osm-9(ok1677). In a genome-wide RNAi screen we identified additional regulators of aqp-8. Many of these regulators are connected to chemosensation by the amphid neurons, e.g., odr-10 and gpa-6, and act as suppressors of aqp-8 expression. We postulate from our results, that aqp-8 plays an important role in sustaining the salt/water balance during a secondary response to hyper-osmotic stress. Upon its activation aqp-8 promotes vesicle docking to the lumen of the excretory cell and thereby enhances the ability to secrete water and transport osmotic active substances or waste products caused by protein damage. In summary, aqp-8 expression and function is tightly regulated by a network consisting of the osmotic stress response, neuronal chemosensation as well as the response to protein damage. These new insights in maintaining the salt/water balance in C. elegans will help to reveal the complex homeostasis network preserved throughout species.
KW  - aquaporin
KW  - osmoregulation
KW  - osmotic stress
KW  - chemosensation
KW  - C. elegans
Y1  - 2017
U6  - https://doi.org/10.3389/fphys.2017.00380
SN  - 1664-042X
VL  - 8
PB  - Frontiers Research Foundation
CY  - Lausanne
ER  -